It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Post-ERCP pancreatitis (PEP) is an acute pancreatitis caused by endoscopic-retrograde-cholangiopancreatography (ERCP). About 10% of patients develop PEP after ERCP. Here we show that gamma-glutamyltransferase 1 (GGT1)-SNP rs5751901 is an eQTL in pancreatic cells associated with PEP and a positive regulator of the IL-6 amplifier. More PEP patients had the GGT1 SNP rs5751901 risk allele (C) than that of non-PEP patients at Hokkaido University Hospital. Additionally, GGT1 expression and IL-6 amplifier activation were increased in PEP pancreas samples with the risk allele. A mechanistic analysis showed that IL-6-mediated STAT3 nuclear translocation and STAT3 phosphorylation were suppressed in GGT1-deficient cells. Furthermore, GGT1 directly associated with gp130, the signal-transducer of IL-6. Importantly, GGT1-deficiency suppressed inflammation development in a STAT3/NF-κB-dependent disease model. Thus, the risk allele of GGT1-SNP rs5751901 is involved in the pathogenesis of PEP via IL-6 amplifier activation. Therefore, the GGT1-STAT3 axis in pancreas may be a prognosis marker and therapeutic target for PEP.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Hokkaido University, Division of Molecular Psychoneuroimmunology, Institute for Genetic Medicine and Graduate School of Medicine, Sapporo, Japan (GRID:grid.39158.36) (ISNI:0000 0001 2173 7691); Hokkaido University Faculty of Medicine and Graduate School of Medicine, Department of Gastroenterology and Hepatology, Sapporo, Japan (GRID:grid.39158.36) (ISNI:0000 0001 2173 7691)
2 Hokkaido University Faculty of Medicine and Graduate School of Medicine, Department of Gastroenterology and Hepatology, Sapporo, Japan (GRID:grid.39158.36) (ISNI:0000 0001 2173 7691)
3 Hokkaido University, Division of Molecular Psychoneuroimmunology, Institute for Genetic Medicine and Graduate School of Medicine, Sapporo, Japan (GRID:grid.39158.36) (ISNI:0000 0001 2173 7691); Northwest University, Institute of Preventive Genomic Medicine, School of Life Sciences, Xian, China (GRID:grid.412262.1) (ISNI:0000 0004 1761 5538)
4 Hokkaido University, Division of Molecular Psychoneuroimmunology, Institute for Genetic Medicine and Graduate School of Medicine, Sapporo, Japan (GRID:grid.39158.36) (ISNI:0000 0001 2173 7691); National Institutes for Quantum Science and Technology (QST), Quantum Immunology Team, Institute for Quantum Life Science, Chiba, Japan (GRID:grid.482503.8) (ISNI:0000 0004 5900 003X)
5 Hokkaido University, Division of Molecular Psychoneuroimmunology, Institute for Genetic Medicine and Graduate School of Medicine, Sapporo, Japan (GRID:grid.39158.36) (ISNI:0000 0001 2173 7691); National Institute for Physiological Sciences, National Institutes of Natural Sciences, Division of Molecular Neuroimmunology, Okazaki, Japan (GRID:grid.467811.d) (ISNI:0000 0001 2272 1771)
6 Hokkaido University, Division of Molecular Psychoneuroimmunology, Institute for Genetic Medicine and Graduate School of Medicine, Sapporo, Japan (GRID:grid.39158.36) (ISNI:0000 0001 2173 7691)
7 Hokkaido University, Division of Molecular Psychoneuroimmunology, Institute for Genetic Medicine and Graduate School of Medicine, Sapporo, Japan (GRID:grid.39158.36) (ISNI:0000 0001 2173 7691); National Institutes for Quantum Science and Technology (QST), Quantum Immunology Team, Institute for Quantum Life Science, Chiba, Japan (GRID:grid.482503.8) (ISNI:0000 0004 5900 003X); Hokkaido University, Institute for Vaccine Research and Development (HU-IVReD), Sapporo, Japan (GRID:grid.39158.36) (ISNI:0000 0001 2173 7691)
8 Hokkaido University, Division of Molecular Psychoneuroimmunology, Institute for Genetic Medicine and Graduate School of Medicine, Sapporo, Japan (GRID:grid.39158.36) (ISNI:0000 0001 2173 7691); Hokkaido University, Institute for Vaccine Research and Development (HU-IVReD), Sapporo, Japan (GRID:grid.39158.36) (ISNI:0000 0001 2173 7691)
9 Hokkaido University Faculty of Medicine, Department of Gastroenterological Surgery II, Sapporo, Japan (GRID:grid.39158.36) (ISNI:0000 0001 2173 7691)
10 Hokkaido University, Division of Molecular Psychoneuroimmunology, Institute for Genetic Medicine and Graduate School of Medicine, Sapporo, Japan (GRID:grid.39158.36) (ISNI:0000 0001 2173 7691); National Institutes for Quantum Science and Technology (QST), Quantum Immunology Team, Institute for Quantum Life Science, Chiba, Japan (GRID:grid.482503.8) (ISNI:0000 0004 5900 003X); National Institute for Physiological Sciences, National Institutes of Natural Sciences, Division of Molecular Neuroimmunology, Okazaki, Japan (GRID:grid.467811.d) (ISNI:0000 0001 2272 1771); Hokkaido University, Institute for Vaccine Research and Development (HU-IVReD), Sapporo, Japan (GRID:grid.39158.36) (ISNI:0000 0001 2173 7691)